LL-37
About
About LL-37
LL-37 is the only member of the cathelicidin family of human antimicrobial peptides, with broad-spectrum activity against bacteria, viruses, and fungi. Beyond its antimicrobial role it is a potent immunomodulator and wound-healing agent with emerging anti-cancer properties. It is studied for chronic infections, biofilm disruption, and inflammatory conditions. Available as a compounded peptide.
Science
Mechanism of Action
Disrupts microbial cell membranes via electrostatic interactions, while also binding LPS to neutralize endotoxin; in host cells it activates toll-like receptors and chemokine receptors to coordinate immune responses.
Dosing
Typical Protocol
100 mcg subcutaneous injection once daily; intranasal and topical formulations used for localized applications.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound is legal to prescribe and dispense through a licensed 503A or 503B compounding pharmacy with a valid prescription. It is not FDA-approved as a finished drug product, but compounding is explicitly permitted under federal law. Quality and sterility standards vary by pharmacy — look for PCAB-accredited compounders.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Find a Verified Provider
See which Vial-verified providers offer LL-37 — with trust scores, legal credentials, and pricing transparency.